Investing
Proceeds From Sale And Maturity Of Available For Sale Securities
Bristol-Myers Squibb Proceeds From Sale And Maturity Of Available For Sale Securities decreased by 10.7% to $359.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 63.2%, from $220.00M to $359.00M. Over 4 years (FY 2021 to FY 2025), Proceeds From Sale And Maturity Of Available For Sale Securities shows a downward trend with a -17.2% CAGR.
Analysis
StatementCash Flow Statement
SectionInvesting
CategoryCapital Allocation
SignalContext dependent
VolatilityVolatile
First reportedQ1 2013
Last reportedQ1 2026Apr 30, 2026
How to read this metric
High proceeds indicate active portfolio rebalancing or the liquidation of assets to meet liquidity needs.
Detailed definition
This represents the cash inflows resulting from the sale, redemption, or maturity of investment securities classified as...
Peer comparison
Standard for insurance companies; reflects the liquidity and turnover of the investment asset base.
Metric ID:
investing_proceeds_from_sale_and_maturity_of_available_f_0efd08Historical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.19B | $984.00M | $1.24B | $2.10B | $1.69B | $1.42B | $1.21B | $57.00M | $270.00M | $365.00M | $41.00M | $747.00M | $75.00M | $238.00M | $62.00M | $220.00M | $524.00M | $829.00M | $402.00M | $359.00M |
| QoQ Change | — | -17.0% | +26.4% | +68.8% | -19.6% | -16.1% | -14.9% | -95.3% | +373.7% | +35.2% | -88.8% | >999% | -90.0% | +217.3% | -73.9% | +254.8% | +138.2% | +58.2% | -51.5% | -10.7% |
| YoY Change | — | — | — | — | +42.3% | +44.0% | -3.1% | -97.3% | -84.0% | -74.2% | -96.6% | >999% | -72.2% | -34.8% | +51.2% | -70.5% | +598.7% | +248.3% | +548.4% | +63.2% |
Range$41.00M – $2.10B
CAGR-22.2%
Avg YoY Growth+142.1%
Median YoY Growth+19.6%
Current Streak2 quarters decline
Proceeds From Sale And Maturity Of Available For Sale Securities at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's proceeds from sale and maturity of available for sale securities?
- Bristol-Myers Squibb (BMY) reported proceeds from sale and maturity of available for sale securities of $359.00M in Q1 2026.
- How has Bristol-Myers Squibb's proceeds from sale and maturity of available for sale securities changed year-over-year?
- Bristol-Myers Squibb's proceeds from sale and maturity of available for sale securities increased by 63.2% year-over-year, from $220.00M to $359.00M.
- What is the long-term trend for Bristol-Myers Squibb's proceeds from sale and maturity of available for sale securities?
- Over 4 years (2021 to 2025), Bristol-Myers Squibb's proceeds from sale and maturity of available for sale securities has grown at a -17.2% compound annual growth rate (CAGR), from $4.20B to $1.98B.
- What does proceeds from sale and maturity of available for sale securities mean?
- Cash received from selling or maturing investment securities.